New, Chiral Phase Transfer Catalysts for Effecting Asymmetric Conjugate Additions of α-Alkyl-α-cyanoacetates to Acetylenic Esters
作者:Xisheng Wang、Masanori Kitamura、Keiji Maruoka
DOI:10.1021/ja068119g
日期:2007.2.1
A new, chiral phasetransfercatalyst has been designed for the development of a general and useful procedure on the hitherto unknown, asymmetric conjugate additions of α-substituted-α-cyanoacetates to acetylenic esters with high enantioselectivity and moderate E/Z selectivity.
Enantioselective organocatalytic substitution of α-cyanoacetates on imidoyl chlorides – synthesis of optically active ketimines
作者:Stefano Santoro、Thomas B. Poulsen、Karl Anker Jørgensen
DOI:10.1039/b715810f
日期:——
The enantioselective substitution of α-cyanoacetates on imidoyl chlorides under phase-transfer catalytic conditions is presented; a simple quinidine-derived phase-transfer catalyst gives access to the products, highly substituted ketimines, in generally good yields and up to 90% ee.
Kinetic and Dynamic Kinetic Resolution of Racemic Tertiary Bromides by Pentanidium‐Catalyzed Phase‐Transfer Azidation
作者:Jingyun Ren、Xu Ban、Xin Zhang、Siu Min Tan、Richmond Lee、Choon‐Hong Tan
DOI:10.1002/anie.202000138
日期:2020.6.2
azides and bromides through pentanidium-catalyzed kinetic resolution (KR) of racemic tertiary bromides under base-free conditions. We found that the absence of water is crucial to attain a high selectivity factor (s). On the other hand, new experimental observations and DFT modeling led us to propose that enantioconvergent azidation of tertiary bromides proceeded through dynamic kinetic resolution
4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS
申请人:FIBROGEN, INC.
公开号:US20150038528A1
公开(公告)日:2015-02-05
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
申请人:FIBROGEN, INC.
公开号:US09409892B2
公开(公告)日:2016-08-09
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.